A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 14 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Aug 2017.
- 14 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2017.
- 16 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.